Discover the portfolio of biological and biosimilar medicines produced and distributed for the entire population.
Medication indicated for the treatment of rare hematologic and immunologic diseases, such as Paroxysmal Nocturnal Hemoglobinuria (PNH).
Medicine indicated to stimulate the production of white blood cells in the bone marrow, helping prevent infections in patients undergoing certain treatments, such as chemotherapy.
Medication indicated for the treatment of autoimmune diseases, such as Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, and polyarticular juvenile idiopathic arthritis.
Medicine indicated for the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Medicine indicated for the treatment of autoimmune diseases, such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis.
Medication indicated for the treatment of ophthalmologic diseases involving neovascularization and increased vascular permeability, such as age-related macular degeneration (AMD) and diabetic macular edema.
Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing the formation of new blood vessels (angiogenesis). It is indicated for the treatment of several diseases, particularly various types of cancer, including: Metastatic colorectal cancer; Advanced or metastatic non-small cell lung cancer, Metastatic breast cancer; Metastatic kidney cancer (advanced renal cell carcinoma), Advanced or recurrent ovarian, fallopian tube, and primary peritoneal cancer; Persistent, recurrent or metastatic cervical cancer.
Immunotherapeutic medication indicated for the treatment of malignant neoplasms, such as advanced unresectable metastatic melanoma.
Medication indicated for the treatment of HER2-positive breast cancer in early-stage and metastatic settings, acting by inhibiting HER2 receptor signaling and contributing to the control of tumor progression.
Medicine indicated for the treatment of early-stage breast cancer, metastatic and non-metastatic breast cancer, and advanced gastric cancer.
A Bionovis is a pioneer in the production and commercialization of biological and biosimilar medicines.
Our search for scientific innovations and highly complex medicines aims to build a healthier Brazil and world for everyone.
© 2026 Bionovis. Companhia Brasileira de Biotecnologia Farmacêutica.
